Spero Therapeutics (SPRO) Change in Accured Expenses (2016 - 2026)

Spero Therapeutics has reported Change in Accured Expenses for 11 years, with the latest figure at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 74.45% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at -$5.0 million (down 279.7% YoY), and the FY2025 full-year result was -$12.1 million, down 208.77% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.4 million, down from -$2.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.3 million in Q3 2024, with the low at -$9.5 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$659294.1 across 5 years, with a median of -$418000.0 in 2022.
• The largest YoY upside for Change in Accured Expenses was 40033.33% in 2024 against a maximum downside of 960.36% in 2024.
• Spero Therapeutics' Change in Accured Expenses stood at $880000.0 in 2022, then tumbled by 100.68% to -$6000.0 in 2023, then surged by 40033.33% to $2.4 million in 2024, then sank by 193.11% to -$2.2 million in 2025, then dropped by 9.19% to -$2.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.4 million (Q1 2026), -$2.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.